-

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

  • Annual Grants Deepen Takeda’s Commitment to Improving Health Through Community-Based Programs
  • Takeda Publishes U.S. Community Impact Report Highlighting Progress toward a More Equitable Health Ecosystem

CAMBRIDGE, Mass.--(BUSINESS WIRE)--See the full release at Takeda.com

Contacts

Media Contact:
Takeda Media Relations
media_relations@takeda.com

Industry:

Takeda Pharmaceutical Company Limited

NYSE:TAK
Release Summary
Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.
Release Versions
English

Contacts

Media Contact:
Takeda Media Relations
media_relations@takeda.com

More News From Takeda Pharmaceutical Company Limited

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (UC), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 The results, presented at the 21st C...

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--FDA Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton as a Potential First-in-Class Therapy for Narcolepsy Type 1...

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment...
Back to Newsroom